BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Facioscapulohumeral Muscular Dystrophy readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Facioscapulohumeral M
 uscular Dystrophy\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07038200-11250@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Delpacibart braxlosiran: Phase 3 readout est. (NCT07038200)
DESCRIPTION:Delpacibart braxlosiran\, phase 3\, Facioscapulohumeral Muscula
 r Dystrophy.\nStudy: A Study to Evaluate Del-brax (Also Referred to as AOC
  1020) in Participants With FSHD\nEstimated primary completion: May 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/delpacibart-braxlosir
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7038200
URL:https://assetmemo.bio/drug/delpacibart-braxlosiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06131983-10768@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SRP-1001: Phase 1/2 readout est. (NCT06131983)
DESCRIPTION:SRP-1001\, phase 1/2\, Facioscapulohumeral Muscular Dystrophy.\
 nStudy: Study of SRP-1001 in Adult and Adolescent Participants With Facios
 capulohumeral Muscular Dystrophy Type 1\nEstimated primary completion: 31 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/srp-10
 01#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6131983
URL:https://assetmemo.bio/drug/srp-1001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547216-11250@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Delpacibart braxlosiran: Phase 2 readout est. (NCT06547216)
DESCRIPTION:Delpacibart braxlosiran\, phase 2\, Facioscapulohumeral Muscula
 r Dystrophy.\nStudy: Phase 2 Open-label Extension Study of AOC 1020 in Par
 ticipants With Facioscapulohumeral Muscular Dystrophy (FSHD)\nEstimated pr
 imary completion: April 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/delpacibart-braxlosiran#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06547216
URL:https://assetmemo.bio/drug/delpacibart-braxlosiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
